TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$230 Million

Revance Therapeutics, Inc.

Follow-on Offering

Bookrunner, September 2022

Revance Therapeutics, Inc.

Revance Therapeutics, Inc. (RVNC) ("Revance") is a commercial stage biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings, including DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL™, a relational commerce platform for aesthetic practices. Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DaxibotulinumtoxinA for Injection in cervical dystonia and upper limb spasticity.